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Salicylazosulfapyridine (SASP) is a sulfon-
amide used to treat inflammatory bowel
disease and ulcerative colitis. Although sev-
eral case reports existed concerning the
ability of SASP to adversely affect male
reproduction, there were few data on fertil-
ity, and no publicly available data on
potential effects ofSASP on female fertil-
ity. It was tested for its effects on reproduc-
tion and fertility in Sprague-Dawley rats
using the RACB protocol. Data on food
and water consumptions, body weights,
and clinical signs from the dose-range-find-
ing study (Task 1) were used to set expo-
sure concentrations for the continuous
cohabitation phase (Task 2) at 100, 200,
and 400 mg/kg, administered bygavage.
Three controls, one low dose, and three
high dose rats died on study. Most ofthese
deaths were related to gavage injury; one
death was from uterine hemorrhage. Water
consumption was increased 10 to 30% in
treated rats, proportional to dose. Dam
weights taken after delivery ofeach litter
showed the high dose females weighed
slightly less than controls (significantly so
for the second and fourth litters); male
weights were reduced only after week 10 in
thehigh dose group, by7 to 12%.
While the mean number of litters per
pair was not changed by SASP, the mean
number ofpups per litter was reduced by
14, 33, and 31% (low to high dose
groups, respectively). The weight of these
pups, adjusted for litter size, was reduced
only at the high dose by 8%. Cumulative
days to deliver each litter was unchanged
by SASP exposure.
The last litter was reared by the dams
until weaning, whereupon the Fl rats from
all dose levels were gavaged at the same
dose received by their parents. Pup survival
and growth during nursing was not
adversely affected by SASP treatment; pups
in the middle dose group weighed more
than controls on postnatal day 14 and 21.
When thelast litterwasweaned, a modi-
fied crossover was performed. This incorpo-
rated a dominant lethal evaluation, wherein
the dams were killed gestational day 19 and
uterine contents examined, using the con-
trol and high dose groups. For the group
mating treated males to control females,
only two thirds of the sperm-positive
females delivered live young. This group
also had a 74% reduction in the number of
live implants per litter, and no increase in
deads. The only increase in "pre-implanta-
tion loss" occurred in treated males.
Collectively, the male data are consistent
with a failure offertilization. Although the
treated females had 20% fewer corpora
lutea, the reductions in number oflive
implants were not statistically significant.
The number ofresorptions perlitterwas not
increased for the treated females.
All Fo groups were killed and necrop-
sied after the crossover. Male body weight
was reduced by 9 and 16% in the middle
and high dose groups; absolute testis
weight was increased by 9% at 100 mg
SASP/kg. Body weight-adjusted epi-
didymis weight was increased by 8%, while
adjusted kidney weight was increased in all
dosed groups, by 8 to 17%. Epididymal
sperm density was reduced only at the
middle dose level (by 23%), while the per-
cent abnormal forms rose from a control
value of0.89% to approximately 4% in all
treated groups.
For females, only the controls and high
dose Fo rats were necropsied. Bodyweights
were reduced at 400 mg/kg by 12%, while
body weight-adjusted liver and kidney
weights were increased by 9%.
No significant microscopic lesions were
seen in the gonads and accessory sex organs
ofrats in any dose group. Because previous
studies in rodents suggested an epididymal
site of action for SASP, serum levels of
acidic epididymal glycoprotein (AEG) mea-
sured by radioimmunoassay were deter-
mined; these were unchanged by SASP
exposure. Also, because SASP is known to
be goiterogenic, blood thyroid-stimulating
hormone (TSH) levels were measured in
the Fo rats. TSH levels were increased only
at the high dose level, to 167% (males) and
232% (females) ofcontrol.
The second generation was mated
within dose groups at approximately post-
natal day 74. There was no significant
change (or trend) in the mating, pregnancy,
or fertility index nor in the number oflive
pups per litter. Adjusted pup weight was
reduced in the middle and high dose
groups by 10 and 12%, respectively. Mean
dam weight was reduced only at the high
dose level by 11%.
After the F2 rats were delivered and
evaluated, Fl rats from all dose levels were
killed and necropsied. Male body weight
was reduced only at the high dose, by 9%,
while adjusted liver weight was reduced
by 6 and 4% (middle and high dose,
respectively), and adjusted kidney weight
was increased at the middle and high
doses by 9 and 11%. Absolute testis
weight was increased in the low through
high dose groups, by 13, 17, and 28%,
respectively. There was a dose-related
increase in thyroid weight which reached
significance at the high dose (18%).
Epididymal sperm density and motility
were generally unchanged, while the per-
cent abnormal forms rose slightly from
0.84% (controls) to approximately 3% in
all treated groups.
Female body weight was reduced by
9% at the top dose. Adjusted kidney
weight was increased at the top dose by
10%, while thyroid weight again showed a
Environmental Health Perspectives - Vol 105, Supplement 1 - February 997 341SALICYLAZOSULFAPYRIDINE
dose-related increase that was significant at
the high dose (37%). Antemortem vaginal
cyclicity was unchanged at any level of
SASP consumption.
Thyroid follicular hyperplasia was
noted microscopically for both sexes; other
microscopic findings were largely inciden-
tal. While acidic epididymal glycoprotein
levels were unchanged by SASP exposure,
serum TSH levels were increased to 168
and 307% ofcontrol values for high dose
males and females, respectively.
In the presence of modest changes in
bodyweight, SASP reduced male fertility at
doses that left most sperm indices function-
ally unchanged. One circulating measure of
epididymal function, serum AEG levels,
were consistently unchanged by SASP.
There were clear indications ofreduced thy-
roid output, registered as increased serum
TSH levels, increased F1 thyroid weights,
microscopic findings ofsuch stimulation,
and increased Fl testis weights. Treated
females were also found, in the dominant
lethal study, to release fewer ova. Overall,
there were no indications of dominant
lethality, but evidence ofdecreased gamete
or gametogenic function, evidenced by
fewer implants from treated males, and
fewercorporalutea in treated females.
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Summary: NTP Reproductive Assessment by Continuous Breeding Study.
NTIS#: PB92203710
Chemical: Salicylazosulfapyridine
CAS#: 599-79-1
Mode of exposure: Gavage
Species/strain: SD rats
F generation Dose concentraton 100 mg/kg 200mg/kg 400mg/kg
Bodyweight --
Kidneyweighta * 1 f *
Liverweight' _ _ _ , . , T
Mortality , _,
Feedconsumption .
Waterconsumption tt
Clinical signs , -__
_IL 17 Mm 'IP 1.11 1 EiN
litters/pair :
Ilivepups/litter. pupwt/litter 4 ,- 4 , 4,
Cumulative daystolinter
Absolutetestis,epididymisweight? 1 , - -
Sexaccessoryglandweight'(prostate,seminalvesicle) . , - -
Epidid. sperm parameters (#, motility, morphology) - -
Estrouscycle length * _ *
Determination ofaffectedsex(crossover) ] Male ] Female [ Both
Doselevel _ ] [ 400mg/kg
F generation Dose concentraton - 100mg/kg 200mg/kg 400 mg/kg
Pupgrowth toweaning -__ 1_,t _ _ .
Mortality __-__,_,_
Adultbodyweight - . ,,4
Kidneyweight' -- t - t,i
Liverweight' -_ 4,- 4,
Feedconsumption _ * _ *
Waterconsumption - - .-
Clinicalsigns -_ -
Fertility index r - = =
$livepups/lifter; pupwt./litter
Absolutetestis,epididymisweight' -- t- j_ _---------- --- t, t
Sexaccessoryglandweight'(prostate,seminalvesicle) t
Epidid.spermparameters(#,motility,morphology) -, t T ----- t ---
Estrous cyclelengh _
Affected sex? Male
Studyconfounders: None
NOAELreproductive toxicity: <100mg/kg
NOAELgeneraltoxicity: <100mg/kg
F1 more sensitivethanFo? No
Postnatal toxicity: No
Legend: -, no change; *, no observation; T or t, statistically significant change (p<0.05); , no change in males orfemales. 'Adjusted for bodyweight.
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